Table 3 The expression of KRT80 in LUAD and LUSC patients and its correlation with clinicopathological parameters.
From: Keratin 80 as a diagnostic biomarker with limited prognostic value in non-small cell lung cancer
Factors | Cases (n) | KRT80 - LUAD | P value | Cases (n) | KRT80 - LUSC | P value | ||
|---|---|---|---|---|---|---|---|---|
Negative | Positive | Negative | Positive | |||||
Area | Â | Â | Â | 0.001 | Â | Â | Â | 0.223 |
Xuanwei | 63 | 9(14.3%) | 54(85.7%) | Â | 9 | 3(33.3%) | 6(66.7%) | Â |
Non-xuanwei | 68 | 28(41.2%) | 40(58.8%) | Â | 35 | 22(62.9%) | 13(37.1%) | Â |
Gender | Â | Â | Â | 0.563 | Â | Â | Â | 0.210 |
Male | 69 | 18(26.0%) | 51(73.9%) | Â | 38 | 23(60.5%) | 15(39.5%) | Â |
Female | 62 | 19(30.6%) | 43(69.3%) | Â | 6 | 2(33.3%) | 4(66.7%) | Â |
Age(y) | Â | Â | Â | 0.473 | Â | Â | Â | 0.533 |
≤ 60 | 91 | 24(26.4%) | 67(73.6%) |  | 14 | 7(50.0%) | 7(50.0%) |  |
>60 | 40 | 13(32.5%) | 27(67.5%) | Â | 30 | 18(60.0%) | 12(40.0%) | Â |
Smoking history | Â | Â | Â | 0.319 | Â | Â | Â | 0.402 |
Yes | 87 | 27(31.0%) | 60(68.9%) | Â | 27 | 14(51.9%) | 13(48.1%) | Â |
No | 44 | 10(22.7%) | 34(77.2%) | Â | 17 | 11(64.7%) | 6(35.3%) | Â |
Drinking history | Â | Â | Â | 0.726 | Â | Â | Â | 0.419 |
Yes | 111 | 32(28.8%) | 79(71.2%) | Â | 12 | 8(66.7%) | 4(33.3%) | Â |
No | 20 | 5(25.0%) | 15(75.0%) | Â | 32 | 17(53.1%) | 15(46.9%) | Â |
Differentiation | Â | Â | Â | 0.786 | Â | Â | Â | 0.948 |
Low | 16 | 6(37.5%) | 10(62.5%) | Â | 7 | 4(57.1%) | 3(42.9%) | Â |
Moderately | 63 | 17(27.0%) | 46(73.0%) | Â | 29 | 16(55.2%) | 13(44.8%) | Â |
High | 14 | 3(21.4%) | 11(78.6%) | Â | 6 | 4(66.7%) | 2(33.3%) | Â |
Unknow | 38 | 11(28.9%) | 27(71.1%) | Â | 2 | 1(50.0%) | 1(50.0%) | Â |
pT stage | Â | Â | Â | 0.569 | Â | Â | Â | 0.923 |
T1 | 78 | 23(29.5%) | 55(70.5%) | Â | 16 | 10(62.5%) | 6(37.5%) | Â |
T2 | 41 | 11(26.8%) | 30(73.2%) | Â | 19 | 10(52.6%) | 9(47.4%) | Â |
T3 | 8 | 1(12.5%) | 7(87.5%) | Â | 9 | 5(55.6%) | 4(44.4%) | Â |
Lymph node metastasis(pN stage) | Â | Â | Â | 0.339 | Â | Â | Â | 0.170 |
Negative | 80 | 25(31.3%) | 55(68.8%) | Â | 23 | 11(47.8%) | 12(52.2%) | Â |
Positive | 51 | 12(23.5%) | 39(76.5%) | Â | 21 | 14(66.7%) | 7(33.3%) | Â |
AJCC stage at diagnosis(pTNM) | Â | Â | Â | 0.471 | Â | Â | Â | 0.489 |
I | 68 | 22(32.4%) | 46(67.6%) | Â | 18 | 10(55.6%) | 8(44.4%) | Â |
II | 21 | 6(28.6%) | 15(71.4%) | Â | 13 | 6(46.2%) | 7(53.8%) | Â |
III | 42 | 9(21.4%) | 33(78.6%) | Â | 13 | 9(69.2%) | 4(30.8%) | Â |
Tumor size(d) | Â | Â | Â | 0.739 | Â | Â | Â | 0.525 |
≤3 cm | 63 | 17(27.0%) | 46(73.0%) |  | 8 | 3(37.5%) | 5(62.5%) |  |
3 < d ≤ 5 cm | 41 | 11(26.8%) | 30(73.2%) |  | 19 | 12(63.2%) | 7(36.8%) |  |
>5 cm | 26 | 9(34.6%) | 17(65.4%) | Â | 16 | 9(56.3%) | 7(43.8%) | Â |
